Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- MTPC to Reorganize Product Marketing Dept. Aiming at Early Market Penetration of New Products
February 29, 2012
- Pfizer Japan to Set Up Rare Disease Division
February 29, 2012
- IMS Japan VP Miyoshi Calls for Focus Shift from Long-Listed Products to Abolishment of Post-Market Expansion Re-Pricing
February 29, 2012
- Major European, US Drug Makers Turning Sights Toward “Mini-buster” Drugs for Rare Diseases
February 29, 2012
- OTS102 Fails to Prolong Survival in Pancreatic Cancer: OncoTherapy Science
February 29, 2012
- Wakamoto to Comarket Bausch & Lomb’s Ocuvite Series of Eye Supplements from April 1
February 29, 2012
- Sanofi Pasteur Files for Approval for Monovalent IPV
February 27, 2012
- Novartis Pharma Submits Afinitor for Add’l Indication of Tuberous Sclerosis
February 27, 2012
- EMA Accepts MAA for Peginesatide for Treatment of Anemia Associated with CKD: Takeda
February 27, 2012
- JCR Pharmaceuticals Announces Favorable Results from PI/II Trial of Stem-cell-based Therapy
February 27, 2012
- Diabetes Treatments: Their Development and Market (2)
February 27, 2012
- Daiichi Sankyo and Terumo Codevelop Intradermal Vaccine
February 24, 2012
- Nichi-Iko and Pfizer Japan Obtain Approval for Cisplatin Generic for Indication of Biliary Tract Cancer
February 24, 2012
- Ajinomoto Pharm. Files NDA for New Oral Bowel Cleansing Agent in Japan
February 24, 2012
- SymBio’s Licensee InnoPharmax Launches Bendamustine in Taiwan
February 24, 2012
- Eli Lilly Receives Approval for Zyprexa, First for Depression in Bipolar Disorder
February 23, 2012
- Use of Rasilez in Combination with ACE Inhibitors, ARBs in Patients with Diabetes to Be Contraindicated in Europe: Novartis
February 23, 2012
- RaQualia Maintains Focus on Pain, GI Diseases in New Midterm Management Plan
February 23, 2012
- Novo Nordisk President Says “Current Pipeline Most Substantial”
February 22, 2012
- Takeda’s Ulcerative Colitis Treatment Vedolizumab Shows Significant Improvement and Remission in Global PIII Trial
February 22, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…